CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...
This month, the European Medicines Agency (EMA) gave marketing authorization to bevacizumab-vikg (Lytenava, Outlook Therapeutics) for the treatment of neovascular (wet) age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results